Schizophrenia Research
Volume 78, Issue 1 , Pages 45-60 , 1 October 2005

Review of longitudinal functional neuroimaging studies of drug treatments in patients with schizophrenia

  • C. Ervin Davis

      Affiliations

    • Department of Psychiatry, University of California San Diego, United States
    • ,
  • Dilip V. Jeste

      Affiliations

    • Department of Psychiatry, University of California San Diego, United States
    • Division of Geriatric Psychiatry, Veterans Affairs San Diego Healthcare System, United States
    • ,
  • Lisa T. Eyler

      Affiliations

    • Department of Psychiatry, University of California San Diego, United States
    • Desert Pacific Mental Illness Research Education and Clinical Center, United States
    • Corresponding Author InformationCorresponding author. Mail Code 151B, VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161. Tel.: +1 858 552 8585x7666; fax: +1 858 642 1458.

Received 21 April 2004 ,Revised 2 May 2005 ,Accepted 9 May 2005.

References 

  1. Bartlett EJ, Brodie JD, Simkowitz P, Schlosser R, Dewey SL, Lindenmayer JP, et al. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am. J. Psychiatry. 1998;155:337–343
  2. Berman I, Merson A, Sison C, Allan E, Schaefer C, Loberboym M, et al. Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients: a pilot study. Psychopharmacol. Bull. 1996;32:95–100
  3. Buchsbaum MS. The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophr. Bull. 1990;16:379–389
  4. Buchsbaum MS, Haier RJ. Functional and anatomical brain imaging: impact on schizophrenia research. Schizophr. Bull. 1987;13:115–132
  5. Buchsbaum MS, Hazlett EA. Functional brain imaging and aging in schizophrenia. Schizophr. Res. 1997;27:129–141
  6. Buchsbaum MS, Wu JC, DeLisi LE, Holcomb HH, Hazlett E, Cooper-Langston K, et al. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. Biol. Psychiatry. 1987;22:479–494
  7. Buchsbaum MS, Potkin SG, Siegel BV, Lohr J, Katz M, Gottschalk LA, et al Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch. Gen. Psychiatry. 1992;49:966–974
  8. Buchsbaum MS, Shihabuddin L, Hazlett EA, Schroder J, Haznedar MM, Powchik P, et al. Kraepelinian and non-Kraepelinian schizophrenia subgroup differences in cerebral metabolic rate. Schizophr. Res. 2002;55:25–40
  9. Corson PW, O'Leary DS, Miller del D, Andreasen NC. The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naive and medicated states. Biol. Psychiatry. 2002;52:855–862
  10. DeLisi LE. Defining the course of brain structural change and plasticity in schizophrenia. Psychiatry Res. 1999;92:1–9
  11. DeLisi LE, Holcomb HH, Cohen RM, Pickar D, Carpenter W, Morihisa JM, et al. Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J. Cereb. Blood Flow Metab. 1985;5:201–206
  12. Franck N, O'Leary DS, Flaum M, Hichwa RD, Andreasen NC. Cerebral blood flow changes associated with Schneiderian first-rank symptoms in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 2002;14:277–282
  13. Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG, et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology. 2003;28:787–794
  14. Gur RE, Resnick SM, Gur RC, Alavi A, Caroff S, Kushner M, et al. Regional brain function in schizophrenia. II. Repeated evaluation with positron emission tomography. Arch. Gen. Psychiatry. 1987;44:126–129
  15. Holcomb HH, Cascella NG, Medoff DR, Gastineau EA, Loats H, Thaker GK, et al. PET-FDG test–retest reliability during a visual discrimination task in schizophrenia. J. Comput. Assist. Tomogr. 1993;17:704–709
  16. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiatry. 1996;153:41–49
  17. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1999;96:13432–13437
  18. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J. Consult. Clin. Psychol. 1991;59:12–19
  19. Jernigan TL, Gamst AC, Fennema-Notestine C, Ostergaard AL. More “mapping” in brain mapping: statistical comparison of effects. Hum. Brain Mapp. 2003;19:90–95
  20. Kindermann SS, Karimi A, Symonds L, Brown GG, Jeste DV. Review of functional magnetic resonance imaging in schizophrenia. Schizophr. Res. 1997;27:143–156
  21. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Frey KN, Hardin M, et al. Clozapine but not haloperidol re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology. 2003;1:1
  22. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Tamminga CA. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol. Psychiatry. 2003;53:601–608
  23. Liddle PF. Cognitive impairment in schizophrenia: its impact on social functioning. Acta Psychiatr. Scand., Suppl. 2000;400:11–16
  24. Manoach DS, Halpern EF, Kramer TS, Chang Y, Goff DC, Rauch SL, et al. Test–retest reliability of a functional MRI working memory paradigm in normal and schizophrenic subjects. Am. J. Psychiatry. 2001;158:955–958
  25. Medoff DR, Holcomb HH, Lahti AC, Tamminga CA. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus. 2001;11:543–550
  26. Miller DD, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol. Psychiatry. 2001;49:704–715
  27. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, et al. Cerebral metabolism and risperidone treatment in schizophrenia. Schizophr. Res. 2003;60:1–7
  28. Moresco RM, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli L, et al. Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. J. Psychopharmacol. 2004;18:355–365
  29. Nahas Z, George MS, Horner MD, Markowitz JS, Li X, Lorberbaum JP, et al. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase. 2003;9:274–282
  30. Ngan ET, Lane CJ, Ruth TJ, Liddle PF. Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change. J. Neurol. Neurosurg. Psychiatry. 2002;72:106–110
  31. Nyberg S, Farde L, Halldin C. Test–retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients. Psychiatry Res. 1996;67:163–171
  32. Sabri O, Erkwoh R, Schreckenberger M, Cremerius U, Schulz G, Dickmann C, et al. Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. J. Nucl. Med. 1997;38:181–188
  33. Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet. 1997;349:1735–1739
  34. Schultz SK, O'Leary DS, Boles Ponto LL, Arndt S, Magnotta V, Watkins GL, et al. Age and regional cerebral blood flow in schizophrenia: age effects in anterior cingulate, frontal, and parietal cortex. J. Neuropsychiatry Clin. Neurosci. 2002;14:19–24
  35. Sharma T. Insights and treatment options for psychiatric disorders guided by functional MRI. J. Clin. Invest. 2003;112:10–18
  36. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr. Res. 2001;49:1–52
  37. Stephan KE, Magnotta VA, White T, Arndt S, Flaum M, O'Leary DS, et al. Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol. Med. 2001;31:1065–1078
  38. Temkin NR, Heaton RK, Grant I, Dikmen SS. Detecting significant change in neuropsychological test performance: a comparison of four models. J. Int. Neuropsychol. Soc. 1999;5:357–369
  39. Weinberger DR. On localizing schizophrenic neuropathology. Schizophr. Bull. 1997;23:537–540
  40. Weinberger DR, Mattay V, Callicott J, Kotrla K, Santha A, van Gelderen P, et al. fMRI applications in schizophrenia research. Neuroimage. 1996;4:S118–S126
  41. Wexler BE, Anderson M, Fulbright RK, Gore JC. Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises. Am. J. Psychiatry. 2000;157:1694–1697
  42. Wykes T, Brammer M, Mellers J, Bray P, Reeder C, Williams C, et al. Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia. Br. J. Psychiatry. 2002;181:144–152
  43. Yurgelun-Todd DA, Coyle JT, Gruber SA, Renshaw PF, Silveri MM, Amico E, et al. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005;138:23–31

PII: S0920-9964(05)00199-4

doi: 10.1016/j.schres.2005.05.009

Schizophrenia Research
Volume 78, Issue 1 , Pages 45-60 , 1 October 2005

Article Tools